-----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: webmaster@www.sec.gov originator-key-asymmetric: mfgwcgyevqgbaqicaf8dsgawrwjaw2snkk9avtbzyzmr6agjlwyk3xmzv3dtinen twsm7vrzladbmyqaionwg5sdw3p6oam5d3tdezxmm7z1t+b+twidaqab mic-info: rsa-md5,rsa, r6tp+u8wc0cwrmkulkiwvwto4jkxxiftpav34m/jicroztnjeghohehfjnmk49hx xuhvrvhmxazt0lxrscoxrq== 0001144204-06-038318.txt : 20060914 0001144204-06-038318.hdr.sgml : 20060914 20060913200744 accession number:		0001144204-06-038318 conformed submission type:	sc 13d public document count:		1 filed as of date:		20060914 date as of change:		20060913 subject company:	 	company data:	 		company conformed name:			advanced medical institute inc. 		central index key:			0001096620 		standard industrial classification:	services-misc health & allied services, nec [8090] 		irs number:				880409144 		state of incorporation:			nv 		fiscal year end:			1231 	filing values: 		form type:		sc 13d 		sec act:		1934 act 		sec file number:	005-80329 		film number:		061089458 	business address:	 		street 1:		c/o advanced medical institute inc. 		street 2:		level 1 204-218 botany road 		city:			alexandria 		state:			c3 		zip:			nsw 2015 		business phone:		61 2 9640 5253 	mail address:	 		street 1:		c/o advanced medical institute inc. 		street 2:		level 1 204-218 botany road 		city:			alexandria 		state:			c3 		zip:			nsw 2015 	former company:	 		former conformed name:	hawksdale financial visions inc 		date of name change:	19991012 filed by:		 	company data:	 		company conformed name:			rrd investments pty ltd 		central index key:			0001374746 		irs number:				000000000 	filing values: 		form type:		sc 13d 	business address:	 		street 1:		65 prospect road 		city:			summer hill 		state:			c3 		zip:			2130 		business phone:		(61) 2 9799 2700 	mail address:	 		street 1:		65 prospect road 		city:			summer hill 		state:			c3 		zip:			2130 sc 13d 1 v052768_sc13d.htm unassociated document securities and exchange commission washington, d.c. 20549 &#160; schedule 13d (rule 13d-102) &#160; information to be included in statmetn pursuant to rule 13d-1(a) and amendments thereto filed pursuant to rule 13d-2(a) (amendment no. __ )* &#160; advanced medical institute inc. (name of issuer) &#160; common stock, par value $.001 per share (title of class of securities) &#160; 00764u109 (cusip number) &#160; mitchell s. nussbaum, esq., loeb &amp; loeb llp, 345 park avenue, new york, ny 10154 (name, address and telephone number of person authorized to receive notices and communications) &#160; september 11, 2006 (date of event which requires filing of this statement) &#160; if the filing person has previously filed a statement on schedule 13g to report the acquisition which is the subject of this schedule 13d, and is filing this schedule because of rule 13d-1(b)(3) or (4), check the following box o . &#160; note: schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. see &#167;240.13d-7 for other parties to whom copies are to be sent. &#160; * the remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. &#160; &#160; the information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the securities exchange act of 1934 ("act") or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act (however, see the notes). &#160; (continued on following pages) (page 1 of 5 pages) &#160; &#160; &#160; &#160; cusip no. 00764u109 13d page 2 of 5 pages &#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; 1 name of reporting person s.s. or i.r.s. identification no. of above person rrd investments pty limited 2 check the appropriate box if a member of a group* &#160; (a) (b) 3 sec use only &#160; 4 source of funds* oo 5 check box if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e) &#160; 6 citizenship or place of organization &#160; australia number of &#160; shares &#160; beneficially &#160; owned by &#160; each &#160; reporting &#160; person with 7 sole voting power &#160; 3,400,000 8 shared voting power &#160; n/a 9 sole dispositive power &#160; 3,400,000 10 shared dispositive power &#160; n/a 11 aggregate amount beneficially owned by each reporting person &#160; 3,400,000 &#160; &#160; 12 check box if the aggregate amount in row (11) excludes certain shares* &#160; &#160; &#160; 13 percent of class represented by amount in row (11) &#160; 6.35% &#160; &#160; 14 type of reporting person* &#160; co &#160; *see instructions before filling out! page&#160;3 of 5 pages &#160; item 1. &#160; security and issuer. &#160; this statement relates to the common stock, par value $.001 per share (&#8220;common stock&#8221;), of advanced medical institute inc., a nevada corporation (the &#8220;company&#8221;). the address of the company's principal executive office is the address of the company's principal executive office is level 1, 204-218 botany road, alexandria, nsw , australia 2015 . &#160; item 2. &#160; identity and background. &#160; (a) &#160; this schedule 13d is filed by rrd investments pty limited. (&#8220;rrd&#8221;), as a shareholder of advanced medical institute inc. &#160; (b) &#160; rrd&#8217;s business address is 65 prospect road, summer hills, nsw 2130, australia. &#160; (c) &#160; rrd is in the business of investing capital into various business entities. the control person and ultimate beneficial owner of rrd is mr. richard doyle, the principal of doyle corporate pty limited, a senior consultant to the company. &#160; (d) &#160; during the past five years, neither rrd , nor to the knowledge of rrd, has any officer, director or control person of rrd, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). &#160; (e) &#160; during the past five years, neither rrd , nor to the knowledge of rrd, has any officer, director or control person of rrd, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. &#160; (f) &#160; rrd was organized under the jurisdiction of australia. &#160; item 3. &#160; source and amount of funds and other consideration. &#160; 3,400,000 shares of common stock were issued to rrd by the company in exchange for the transfer and assignment of 34,000,000 ordinary shares of worldwide pe patent holdco pty limited, a corporation formed under the laws of australia (&#8220;worldwide pe&#8221;), pursuant to the terms of a share exchange agreement dated as of september 8, 2006 (the &#8220;worldwide pe transaction&#8221;). &#160; a copy of such agreement is filed as exhibit 10.1 to the company&#8217;s current report on form 8-k dated september 8, 2006 and filed with the securities and exchange commission on september 11, 2006. &#160; item 4. &#160; purpose of transaction. &#160; rrd acquired the shares in connection with the worldwide pe transaction and the pe transaction. the purpose of the acquisition and the exchange was for the company to obtain 100% ownership of each of worldwide pe and pe, each of which are holding companies formed under the laws of australia. &#160; other than as set forth below, rrd does not have any plans or proposals which relate to or would result in: &#160; (a) the acquisition by any person of additional securities of the company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation , involving the company or any of its subsidiaries; &#160; page&#160;4 of 5 pages &#160; (c) a sale or transfer of a material amount of assets of the company or of any of its subsidiaries; (d) any change in the present board of directors or management of the company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the company; (f) any other material change in the company&#8217;s business or corporate structure; (g) changes in the company&#8217;s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any other person; (h) causing a class of securities of the company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the company becoming eligible for termination of registration pursuant to section 12(g)(4) of the securities act; or (j) any similar action to those enumerated above. &#160; item 5. &#160; interest in securities of the company. &#160; (a) &#160; rrd is the beneficial owner of an aggregate of 3,400,000 shares of common stock, representing approximately 6.35% of the total issued and outstanding shares of common stock. &#160; (b) &#160; rrd has the sole power to vote or to direct the vote, and sole power to dispose or direct the disposition of the 3,400,000 shares of common stock beneficially owned by it individually. &#160; (c) &#160; other than the acquisition of the shares as reported in this schedule 13d, rrd has not effected any transactions in the common stock of the company in the past sixty (60) days. &#160; (d) &#160; to the knowledge of rrd, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares owned by him individually. &#160; (e) &#160; not applicable. &#160; item 6. &#160; contracts, arrangements, understandings or relationships with respect to securities of the issuer. &#160; rrd is not a party to any contracts, arrangements, understandings or relationship with respect to the securities of the company. &#160; item 7. materials to be filed as exhibits. &#160; none. &#160; page 5 of 5 pages &#160; after reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. &#160; &#160; dated: &#160; september 13, 2006 rrd investments pty limited by: /s/ richard doyle&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; name: richard doyle title: director &#160; &#160; &#160; &#160; &#160; -----end privacy-enhanced message----- 